粉样神经病变的临床病理特征:四十年的经验
Asha Unchagi1, Shilpa Rao1, Madhu Nagappa2
1Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
Neurology India
|July 23, 2024
概括
粉样神经病变是一种罕见的疾病 (0.28%的神经活检),通常呈现为小纤维神经病变. 通过神经活检进行早期诊断对于有效管理这种外围神经病变至关重要.
科学领域:
- 神经学 神经学
- 病理学 病理学 病理学
- 遗传学 遗传学 是一个
背景情况:
- 周围神经病变是一种已知的原发性或家族性粉样性粉症的表现.
- 印度对粉样神经病的研究显著有限,这凸显了区域研究中的差距.
研究的目的:
- 审查粉样神经病变的临床和病理特征.
- 为了分析39年的经验,诊断出粉样神经病变的病例.
主要方法:
- 从被诊断的粉样神经病变病例的临床和病理数据的回顾性审查.
- 在39年的时间里 (1981-2019) 分析了外围神经活检结果.
主要成果:
- 确定了55例粉样神经病变,占外围神经活检的0.28%.
- 大多数患者呈现小纤维神经病变 (85%),感觉运动症状 (72%) 和自主参与 (35.8%).
- 神经活检显示了特征性粉样蛋白沉积物,主要围绕着内管微血管,优选的是小髓纤维的损失.
结论:
- 粉样神经病变是一种不常见的诊断,强调了神经活检的诊断重要性.
- 提高对粉样蛋白沉积物的认识和勤奋的搜索对于早期诊断至关重要,特别是随着治疗方法的进步.
更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.6K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.3K
相关概念视频
Amyloid Fibrils
5.1K
5.1K
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
